UBS Group’s Oncobiologics, Inc. Series B Warrant ONSIZ Stock Holding History

UBS Group’s Portfolio ONSIZ Stock Details ONSIZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2,935	Closed	–	–	8562
2018 Q1	$0	Buy	2,935 +2,185	+291%	+$86	﹤0.01%	8461
2017 Q4	$0	Hold	750	–	–	﹤0.01%	8343
2017 Q3	$0	Sell	750 -3,300	-81%	-$217	﹤0.01%	8242
2017 Q2	$0	Buy	4,050 +2,926	+260%	+$533	﹤0.01%	8257
2017 Q1	$0	Sell	1,124 -2,748	-71%	-$1.19K	﹤0.01%	8262
2016 Q4	$3K	Sell	3,872 -2,528	-40%	-$1.95K	﹤0.01%	7463
2016 Q3	$7K	Buy	6,400 +5,650	+753%	+$4.12K	﹤0.01%	7016
2016 Q2	$0	Buy	+750	New	+$395	﹤0.01%	8175

UBS Group's ONSIZ Position: Q2 2018 in Review

UBS Group sold out of Oncobiologics, Inc. Series B Warrant (ONSIZ) in Q2 2018, closing a stake of 2,935 shares.

UBS Group first reported a position in ONSIZ in Q2 2016 and held it in 8 quarters. The position peaked at $7K in Q3 2016. 0 funds tracked by Wall St. Rank hold ONSIZ as of Q2 2018.

UBS Group reported no remaining Oncobiologics, Inc. Series B Warrant position as of Q2 2018 after selling out during the quarter.
UBS Group sold 2,935 Oncobiologics, Inc. Series B Warrant shares in Q2 2018.
UBS Group first reported a position in Oncobiologics, Inc. Series B Warrant in Q2 2016 and held it in 8 quarters.
UBS Group's Oncobiologics, Inc. Series B Warrant position peaked at $7K in Q3 2016.
0 funds tracked by Wall St. Rank held Oncobiologics, Inc. Series B Warrant as of Q2 2018.

Based on UBS Group's 13F filing for Q2 2018, filed 14 Aug 2018.